Selskabets formål er at drive virksomhed indenfor bioteknologi og anden dermed i forbindelse stående virksomhed, herunder at eje datterselskaber og kapitalandele i forbindelse hermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 324.9 mio. | 78.4 mio. | 425.4 mio. | 111.3 mio. | 167 | |
CVR: 30799968
Secondary names: NORDIC BIOSCIENCE ASSAY DEVELOPMENT A/S, NORDIC BIOSCIENCE COMPOUND DEVELOPMENT A/S
3 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 998 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Nordic Bioscience A/S demonstrates a strong financial health with a notable increase in revenue and profit in 2024, achieving 324.9 million DKK in revenue and 78.4 million DKK in profit, marking a significant growth from 236.4 million DKK in revenue and 33.7 million DKK in profit in 2023. The company has shown fluctuating revenues over the past few years, with a peak in 2022 at 313.6 million DKK, but overall, the trend appears positive. A key strength lies in its equity position, which has increased from 61.6 million DKK in 2023 to 111.3 million DKK in 2024, indicating a solid foundation for future growth. However, the variability in profit margins suggests potential concerns regarding operational efficiency. Positioned within the research and experimental development sector, Nordic Bioscience A/S is well-placed to leverage its financial stability for further advancements in the industry.
AI-generated summary
Companies in the same industry and area
CVR 40848460
CVR 45737950
CVR 40343040
CVR 29833125
CVR 31707129
companydata.dk